title: Doxazosin in patients with hypertension.
abstract: The antihypertensive effects and steady-state pharmacokinetics of doxazosin, as well as the bioequivalence of four dosage forms, were studied in 25 hypertensive patients. For an 8 mg daily dose mean Cmax at steady-state for all patients was 108 ng/ml; the mean tmax was 1.8 h. The mean terminal elimination half-life was 22 h. The four tablets containing 1, 2, 4, or 8 mg of doxazosin were bioequivalent in delivering the 8 mg dose. In patients with mild to moderate hypertension, 26-day treatment with doxazosin resulted in blood pressure reduction of 10/7 mmHg in the supine and 13/18 mmHg in the standing position. Adverse effects were generally mild and of brief duration.
authors.affiliation: University of Arizona College of Medicine Tucson 85724.
authors.forename: K A
authors.initials: KA
authors.lastname: Conrad
authors.forename: T C
authors.initials: TC
authors.lastname: Fagan
authors.forename: M J
authors.initials: MJ
authors.lastname: Mackie
authors.forename: P V
authors.initials: PV
authors.lastname: Mayshar
authors.forename: S
authors.initials: S
authors.lastname: Lee
authors.forename: J F
authors.initials: JF
authors.lastname: Souhrada
authors.forename: F C
authors.initials: FC
authors.lastname: Falkner
authors.forename: J D
authors.initials: JD
authors.lastname: Lazar
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D017292:Doxazosin; D005260:Female; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D017292:Doxazosin; D011224:Prazosin